Hadasit Medical Research Services and Development Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadasit Medical Research Services and Development Company

Christian-albrechts-universitat Zu Kiel

Theravir Management L.p.

Hadasit & Medical Research Services & Development Company, Ltd.

Emory University

Eithan Galun

Raymond F Schinazi

Hubert E Blum

Jonathan H Axelrod

Aaron Lewis

Franck Amblard

Stefan Rose-John

Alexandra Manevitch

Bryan D Cox

Hilla Giladi

Orit Nahor

Zichria Zakay-Rones

Charles S Irving

Amos Panet

Mali Ketzinel Gilad

Evelyn Zeira

Malte Peters

Nofar Rosenberg

Chofit Chai

Dayana Yaish

Zohar Shmuelian

Evgeniya Greenbaum

Linda Rasooly

Arnold I Freeman

Yael Nehemia

Daniel Barkan

Ytzhack Marmary

Yitzchak Hemo

Artium Khatchatouriants

Evelyne Zeira

Sagit Arbel Alon

Yael Hantz

Alina Simerzin

Jonathan Axelrod

Itzhack Marmary

The present invention provides compositions having one or more agents capable of increasing expression of one or more endogenous tumor suppressive mi RNAs in one or more producing cells, such that the endogenous mi RNAs can affect one or more target cancer cells. Further provided are method and uses thereof for treating cancer.

Tumor suppressive microRNAs for cancer therapy

The present invention provides miR-122* as a functional microRNA molecule, compositions comprising the same and uses thereof for treatment of various conditions, such as, cancer. Further provided are methods for increasing the expression, stability and/or activity of p53 in a target cell or method for inducing cancer cell death, the methods comprising introducing into the cell a miR-122* polynucleotide molecule or a vector expressing or encoding the same.

miR-122* as an active micro-RNA, compositions comprising the same and uses thereof

A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.

Controlled laser treatment for non-invasive tissue alteration, treatment and diagnostics with minimal collateral damage

The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.

Methods for the treatment of radiation or chemotherapy-induced tissue damage

The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.

Methods for the treatment of renal failure

The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.

Compositions of NDV and methods of use thereof for treatment of cancer

The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hepatocytes and other HBV-permissive cells, the active agent being present in sufficient amount to competitively bind to at least one of the sites and thereby to prevent hIL6-mediated HBV infection of hepatocytes and other HBV-permissive cells.

Pharmaceutical composition for treating hepatitis B virus (HBV) infection

A method for administering the HAV vaccine to a subject by absorption through a mucosal tissue, particularly through the mucosa of the rectum. The method of the present invention enables the HAV vaccine to be administered to the subject rectally, for example as a suppository or other rectal dosage form, and to successfully immunize the subject against HAV. Thus, the present invention overcomes problems of background art methods of administration, such as systemic administration by injection for example, which require needles, and which are difficult and expensive to perform.

Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine

A method for treating an injury of a liver of a subject with a composition featuring a pharmaceutically acceptable amount of an IL-6/sIL-6R complex, preferably Hyper-IL-6. The composition is administered to the subject such that the injury to the liver is treated.

IL-6/SIL-6R complex for promotion of liver functions

Growing community of inventors

Har Adar, Israel

Eithan Galun